Insiders · ETON

ETON insider transactions

Eton Pharmaceuticals Inc. (ETON) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ETON insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Eton Pharmaceuticals Inc., latest first. Follow anyone to get their next filing.

• Paul V MaierDirector-$5.91M
• David KrempaChief Business Officer, since March 2023-$5.36M
• Sean BrynjelsenPresident & CEO, Director+$94K-$13.5M
• Danka RadosavljevicChief Operating Officer, since July 2026
• Charles J CasamentoDirector
• Judith M. MatthewsChief Financial Officer, since June 2026
• Ipek Erdogan-TrinkausChief Commercial Officer, since December 2024
• Norbert G RiedelDirector
• Jennifer McKie AdamsDirector, since March 2021-$1.62M
• Opaleye Management Inc.10% owner, since September 2024+$1.14M-$17.9M
• James R. GruberChief Financial Officer, since April 2022-$674K
• William Wilson TroutmanOfficer+$22.2K
• Harrow Health, Inc.10% owner-$10.6M

Recent Form 3, 4, and 5 filings for ETON

• 33d
  Chief Business Officer Krempa David sold $229,406 worth of shares (4,166 units at $55.07) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 69d
  Amendment: Director Maier Paul V sold $2,953,572 worth of shares (50,000 units at $59.07) and exercised 62,500 shares at a strike of $4.49, increasing direct ownership by 21% to 72,245 units (SEC Form 4)

  4/A - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 72d
  Director Maier Paul V exercised 50,000 shares at a strike of $3.78 and sold $2,953,572 worth of shares (50,000 units at $59.07) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 76d
  Chief Business Officer Krempa David sold $1,626,750 worth of shares (25,000 units at $65.07) and exercised 25,000 shares at a strike of $7.31 (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 80d
  President & CEO Brynjelsen Sean sold $6,087,773 worth of shares (100,000 units at $60.88), decreasing direct ownership by 9% to 961,194 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 88d
  New insider Radosavljevic Danka claimed ownership of 22,473 shares (SEC Form 3)

  3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by Director Casamento Charles J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by Chief Financial Officer Matthews Judith M.

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by Chief Commercial Officer Erdogan-Trinkaus Ipek

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by President & CEO Brynjelsen Sean

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by Chief Business Officer Krempa David

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by Director Maier Paul V

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by Director Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 96d
  SEC Form 4 filed by Director Adams Jennifer Mckie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 114d
  Amendment: Large owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)

  4/A - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 115d
  Large owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 117d
  President & CEO Brynjelsen Sean exercised 227,500 shares at a strike of $1.20, increasing direct ownership by 27% to 1,061,194 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 118d
  Chief Business Officer Krempa David converted options into 10,000 shares, increasing direct ownership by 37% to 37,025 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 124d
  Large owner Opaleye Management Inc. sold $4,768,637 worth of shares (126,685 units at $37.64) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 131d
  SEC Form 4 filed by Chief Business Officer Krempa David

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 144d
  Director Adams Jennifer Mckie exercised 50,000 shares at a strike of $3.78 and sold $1,623,795 worth of shares (50,000 units at $32.48) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 160d
  SEC Form 3 filed by new insider Matthews Judith M.

  3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 163d
  President & CEO Brynjelsen Sean sold $3,825,717 worth of shares (120,000 units at $31.88), decreasing direct ownership by 13% to 833,694 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 165d
  Chief Business Officer Krempa David exercised 87,794 shares at a strike of $2.32 and sold $3,229,923 worth of shares (100,000 units at $32.30), decreasing direct ownership by 33% to 25,249 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 200d
  SEC Form 4 filed by Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 276d
  Director Riedel Norbert G exercised 30,000 in-the-money shares at a strike of $4.42, increasing direct ownership by 600% to 35,000 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  SEC Form 4 filed by Director Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  SEC Form 4 filed by Director Adams Jennifer Mckie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  SEC Form 4 filed by Director Casamento Charles J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  SEC Form 4 filed by Director Maier Paul V

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  SEC Form 4 filed by Chief Commercial Officer Erdogan-Trinkaus Ipek

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  President & CEO Brynjelsen Sean covered exercise/tax liability with 5,015 shares, decreasing direct ownership by 0.17% to 2,889,266 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  Chief Business Officer Krempa David covered exercise/tax liability with 1,942 shares, decreasing direct ownership by 0.31% to 630,238 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 298d
  Chief Financial Officer Gruber James R. covered exercise/tax liability with 2,293 shares, decreasing direct ownership by 1% to 213,420 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 331d
  Chief Commercial Officer Erdogan-Trinkaus Ipek covered exercise/tax liability with 85 shares, decreasing direct ownership by 3% to 2,403 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 331d
  Chief Business Officer Krempa David covered exercise/tax liability with 6,264 shares, decreasing direct ownership by 0.98% to 632,180 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 331d
  Chief Financial Officer Gruber James R. covered exercise/tax liability with 4,542 shares, decreasing direct ownership by 2% to 215,713 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 331d
  President & CEO Brynjelsen Sean covered exercise/tax liability with 6,732 shares, decreasing direct ownership by 0.23% to 2,894,281 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 445d
  Chief Financial Officer Gruber James R. sold $673,714 worth of shares (41,713 units at $16.15), decreasing direct ownership by 16% to 204,753 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 510d
  Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 514d
  Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 521d
  President & CEO Brynjelsen Sean sold $3,592,611 worth of shares (210,000 units at $17.11), decreasing direct ownership by 7% to 2,873,513 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  SEC Form 4 filed by Director Adams Jennifer Mckie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  Director Riedel Norbert G exercised 102,400 shares at a strike of $3.65, increasing direct ownership by 171% to 162,145 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  SEC Form 4 filed by Director Casamento Charles J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  SEC Form 4 filed by Director Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  SEC Form 4 filed by Director Maier Paul V

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  SEC Form 4 filed by President & CEO Brynjelsen Sean

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  SEC Form 4 filed by Chief Business Officer Krempa David

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 671d
  SEC Form 4 filed by Chief Financial Officer Gruber James R.

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 699d
  SEC Form 3 filed by new insider Erdogan-Trinkaus Ipek

  3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 744d
  Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 761d
  Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 765d
  SEC Form 4 filed by Chief Business Officer Krempa David

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 787d
  Large owner Opaleye Management Inc. bought $504,875 worth of shares (107,500 units at $4.70) (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 787d
  New insider Opaleye Management Inc. claimed ownership of 2,672,500 shares (SEC Form 3)

  3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 997d
  SEC Form 4 filed by Gruber James R.

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 997d
  SEC Form 4 filed by Adams Jennifer Mckie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 997d
  SEC Form 4 filed by Brynjelsen Sean

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 997d
  SEC Form 4 filed by Casamento Charles J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)